In this line, Therapeutic Drug Monitoring (TDM) of anti-TNF has been proven to prevent immunogenicity and to achieve better long-term outcomes in terms of IBD-related surgery or hospitalization [23,24,25]. This evidence concerns the gene TNF and inflammatory bowel disease.